Komori

Summary of Q&A from the briefing on the financial results for the second quarter of the fiscal year ending March 2027

Q&A summaryFirst half, FY ending Mar 2027Published 2026-11-19 15:30

The company has published questions raised at the earnings briefing and its responses on joint research, development plans, financing, licensing-out negotiations, and continued listing criteria. No new earnings figures or changes to the full-year forecast were presented.

In short

  • The joint research agreement with KYORIN Pharmaceutical Co.,Ltd. is part of a growth strategy to enhance business value through collaboration with external partners.
  • The development policy for PPMX-T004 remains unchanged, and master cell bank manufacturing is planned to begin in January 2027.
  • Financing through the 29th stock acquisition rights was completed at approximately ¥700 million, compared with the planned approximately ¥930 million, and the ¥150 million development cost for PPMX-T004 is scheduled to be incurred going forward.

What they reported

this period against the same period a year earlier, and where they now expect the year to end

Sales

¥52.0m−13.3%vs a year earlier
H1 FY26¥60.0mH1 FY27¥52.0m
FY25FY26FY27 · this year203040¥mQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4+52%−54%this yearvs same quarter last yearlast year
Sales by quarter
Period¥m
FY25 Q120.0
FY25 Q239.0
FY25 Q324.0
FY25 Q437.0
FY26 Q123.0
FY26 Q237.0
FY26 Q343.0
FY26 Q432.0
FY27 Q135.0
FY27 Q217.0

Operating profit

−¥411.0mloss widenedvs a year earlier
H1 FY26−¥399.0mH1 FY27−¥411.0m
FY25FY26FY27 · this year-220-200-180¥mQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4▲▼this yearvs same quarter last yearlast year
Operating profit by quarter
Period¥m
FY25 Q1-221.0
FY25 Q2-193.0
FY25 Q3-216.0
FY25 Q4-196.0
FY26 Q1-218.0
FY26 Q2-181.0
FY26 Q3-174.0
FY26 Q4-171.0
FY27 Q1-204.0
FY27 Q2-207.0

Ordinary profit

−¥394.0mloss widenedvs a year earlier
H1 FY26−¥345.0mH1 FY27−¥394.0m
FY25FY26FY27 · this year-220-200-180-160¥mQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4▼this yearvs same quarter last yearlast year
Ordinary profit by quarter
Period¥m
FY25 Q1-214.0
FY25 Q2-213.0
FY25 Q3-197.0
FY25 Q4-205.0
FY26 Q1-171.0
FY26 Q2-174.0
FY26 Q3-164.0
FY26 Q4-169.0
FY27 Q1-201.0
FY27 Q2-193.0

Net profit

−¥399.0mloss widenedvs a year earlier
H1 FY26−¥379.0mH1 FY27−¥399.0m
FY25FY26FY27 · this year-250-200-150¥mQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4▼▲this yearvs same quarter last yearlast year
Net profit by quarter
Period¥m
FY25 Q1-219.0
FY25 Q2-276.0
FY25 Q3-199.0
FY25 Q4-210.0
FY26 Q1-176.0
FY26 Q2-203.0
FY26 Q3-168.0
FY26 Q4-171.0
FY27 Q1-202.0
FY27 Q2-197.0

Everything else in the deck

New initiatives

what they said they're starting
  • The company has entered into a joint research agreement with KYORIN Pharmaceutical Co.,Ltd. and will pursue business expansion through collaboration with external partners.
  • For PPMX-T004, the company will begin master cell bank manufacturing in January 2027.

What decks usually leave out

COMPUTED = worked out by Komori from reported numbers; the rest are stated in this deck

Margins and overheads

where each ¥100 of sales goes
Computed
a year ago-665.0%now-790.4%

Financial targets

the last five years against the target (green band), where one is stated
Computed
Return on equity-54.2%
profit earned on shareholders' money
+9.7 pts on last year
-66%-46%-26%FY23FY24FY25FY26FY23: -28.3%FY24: -58.2%FY25: -63.9%FY26: -54.2%-54.2%
Return on equity
Period%
FY23-28.3
FY24-58.2
FY25-63.9
FY26-54.2
Equity ratio62.7%
how much of the balance sheet is owned outright
−7.4 pts on last year
61%79%97%FY22FY23FY24FY25FY26FY27FY22: 95.5%FY23: 92.1%FY24: 78.2%FY25: 74.4%FY26: 70.1%FY27: 62.7%62.7%
Equity ratio
Period%
FY2295.5
FY2392.1
FY2478.2
FY2574.4
FY2670.1
FY2762.7

Yearly figures are computed by Komori from J-Quants results data (ROE = net profit ÷ average equity). The last point is this year's forecast or latest figure. Targets show only when this deck states them.

Investor Q&A

what investors pushed on, and whether they got an answer
1 of 7answers dodged the question
where the questions went
Joint research agreements and growth strategy
1
PPMX-T004 development policy
1
Use of financing proceeds and future financing
1
PPMX-T003 ASH presentation and licensing-out activities
1
Future impact of PTX3 approval on financial performance
1
PPMX-T003 licensing-out negotiations and additional clinical trials
1
Growth Market continued listing criteria
1
Joint research agreements and growth strategy

What was the background to the joint research agreements with KYORIN Pharmaceutical Co.,Ltd., ASKA Pharmaceutical Co., Ltd., and Eurus Therapeutics, and what are the prospects for their development?

The company positions expansion through collaboration as one of its growth strategies and aims to maximize business value by combining its technologies and drug discovery platform with collaboration and alliances involving external partners.

Hedged
PPMX-T004 development policy

Has the policy of beginning master cell bank manufacturing in January 2027 remained unchanged following the preliminary toxicity studies?

There has been no change to the development policy, and manufacturing is planned to begin in January 2027 as scheduled.

Straight
Use of financing proceeds and future financing

How have the proceeds from past financings been used, and what are the prospects for future financing?

Approximately ¥700 million was raised against the plan for approximately ¥930 million, and the ¥150 million development cost for PPMX-T004 will be spent going forward. There is nothing the company can explain at this time regarding future financing.

Hedged
PPMX-T003 ASH presentation and licensing-out activities

What impact will the presentation of the clinical research results at ASH have on licensing-out activities for PPMX-T003?

The presentation provides supplementary information to the Phase I trial data, but the impact on licensing-out activities will be determined by the companies considering in-licensing the product.

Hedged
Future impact of PTX3 approval on financial performance

What is the expected future impact of PTX3 approval on financial performance?

The company cannot respond because it has not disclosed the details of the joint research agreement.

Dodged
PPMX-T003 licensing-out negotiations and additional clinical trials

What is the progress of the licensing-out negotiations, whether there are any expressions of interest, the possibility of conducting the next clinical trial in-house, and the reasons the negotiations are taking time?

The company is exchanging technical information with several interested companies and believes that PPMX-T003 offers product advantages and addresses medical needs.

Hedged
Growth Market continued listing criteria

What is the company's future management policy in light of the review of the continued listing criteria?

The company will research developments at other companies and in the industry, consider various measures, and seek to meet the criteria by increasing corporate value.

Hedged

How straight each answer was: a number or commitment = straight; a direction without a number = hedged; no answer = dodged.

Not mentioned in this deck

16
Company KPIsBy businessWhat movedCapital spendingShare buybackDividendSelf-rating against planForecast assumptionsRisks priced into the forecastMid-term plan targetsA stated financial targetOrders and backlogPrice and volumeStore or site countHeadcountMarket size and share
Summary of Q&A from the briefing on the financial results for the second quarter of the fiscal year ending March 2027 | Perseus Proteomics Inc. (4882) timely disclosure | Komori